pegylated interferon-alfa 2a

PreclinicalSmall molecule

pegylated interferon-alfa 2a is one of 39 small molecule programs targeting Hepatitis B. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis BActive, not recruiting

ChronicCompleted

Hepatitis BPreclinical

Active, not recruiting

ChronicPreclinical

Completed

Competition

Competitive Landscape

44 competitors in Hepatitis B

#DrugCompanyPhaseTrials

Vemlidy

Gilead

Approved

7 2

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

16 3

Emtriva

Gilead

Approved

1 4

Selzentry

GSK

Approved

1 5

Epivir

GGlaxo Dba Glaxosmithkline

Approved

8 6

Sunlenca

Cabenuva

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

2 9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Retrovir

BBp Consulting, Inc

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis C16 trials

Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C

Completed·NNational Taiwan University Hospital·Phase 4·NCT00917358·42 enrolled

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00100581·2 enrolled

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT00372385·334 enrolled

Show 13 more trials

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Completed·TTanta University·Phase 4·NCT02992457·10,000 enrolled

A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C

Completed· Roche logo

Roche··NCT01659567·516 enrolled

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01447394

Australian Trial in Acute Hepatitis C

Completed·KKirby Institute·Phase 4·NCT00192569·167 enrolled

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT00420784·465 enrolled

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Terminated· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 3·NCT01467479·185 enrolled

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT00535847·117 enrolled

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 3·NCT00627926·1,095 enrolled

Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]

Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 2/3·NCT03480932·150 enrolled

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01428063·276 enrolled

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01448044·152 enrolled

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT00336479·263 enrolled

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01012895·215 enrolled

Chronic Hepatitis15 trials

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Completed· Roche logo

Roche·Phase 3·NCT02263079·62 enrolled

Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)

Completed·—·Phase 2/3·NCT01276756·100 enrolled

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

Completed· Roche logo

Roche·Phase 3·NCT00483938·236 enrolled

Show 12 more trials

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Completed· Roche logo

Roche·Phase 3·NCT00800735·30 enrolled

A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

Completed·SShanghai HEP Pharmaceutical Co., Ltd.·Phase 2·NCT05244057·8 enrolled

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01257204·196 enrolled

Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

Terminated·UUniversity Hospital, Bonn·Phase 3·NCT00221286·2 enrolled

Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment

Completed·—·Phase 4·NCT00226382·50 enrolled

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

Completed·BBausch Health Americas, Inc.·Phase 3·NCT00093093·900 enrolled

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure

Terminated· Roche logo

Roche··NCT01798576·282 enrolled

Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)

Completed· Roche logo

Roche··NCT02106156·10,228 enrolled

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Completed· GSK logo

GSK·Phase 2·NCT01439373·16 enrolled

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Terminated· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 4·NCT01467492·121 enrolled

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01513941·163 enrolled

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01498068·36 enrolled

TED2 trials

HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients

Completed·JJosé Antonio Carrion·N/A·NCT02743182·119 enrolled

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

Completed·EEiger BioPharmaceuticals·Phase 2·NCT02430194·55 enrolled

Liver Transplant2 trials

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Terminated· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT01467505·61 enrolled

An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01571583·74 enrolled

Polycythemia Vera1 trial

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Completed·PPV-Nord·Phase 2·NCT00241241·40 enrolled

11 more indications

Treatment1 trial

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Completed· Roche logo

Roche·Phase 2/3·NCT02829775·9 enrolled

HIV1 trial

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00078442·12 enrolled

Interleukin1 trial

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Terminated· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 3·NCT01459913·239 enrolled

Hepatocellular Carcinoma1 trial

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT01821963·1 enrolled

Chronic1 trial

HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated

Completed·—·N/A·NCT01471535·20 enrolled

Chronic Hepatitis B Virus Infection1 trial

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Completed·VVir Biotechnology, Inc.·Phase 2·NCT04412863·84 enrolled

HCV1 trial

Directly Observed Therapy for HCV in Chennai, India

Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 2·NCT02541409·50 enrolled

Hepatitis C Virus Infection1 trial

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Completed·TTibotec BVBA·Phase 2·NCT00580801·24 enrolled

Safety and Efficacy1 trial

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01425970·210 enrolled

Hepatitis B1 trial

Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy

Unknown status·HHuashan Hospital··NCT02589652·294 enrolled

Chronic Hepatitis C Virus Infection1 trial

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01241760·744 enrolled

Sources

References

[1]
ClinicalTrials.gov — 47 trial records for pegylated interferon-alfa 2a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pegylated interferon-alfa 2a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pegylated interferon-alfa 2a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Vertex Pharmaceuticals

pegylated interferon-alfa 2a

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis C16 trials

Chronic Hepatitis15 trials

TED2 trials

Liver Transplant2 trials

Polycythemia Vera1 trial

Treatment1 trial

HIV1 trial

Interleukin1 trial

Hepatocellular Carcinoma1 trial

Chronic1 trial

Chronic Hepatitis B Virus Infection1 trial

HCV1 trial

Hepatitis C Virus Infection1 trial

Safety and Efficacy1 trial

Hepatitis B1 trial

Chronic Hepatitis C Virus Infection1 trial

References

Drug Info

Quick Facts

Related News